Identification

Name
Methylergometrine
Accession Number
DB00353  (APRD00739)
Type
Small Molecule
Groups
Approved
Description

A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)

Structure
Thumb
Synonyms
  • 9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide
  • D-lysergic acid 1-butanolamide
  • Ergotyl
  • Methylergobasin
  • Methylergometrin
  • Méthylergométrine
  • Methylergometrine
  • Methylergometrinum
  • Methylergonovine
  • Metilergometrina
Product Ingredients
IngredientUNIICASInChI Key
Methylergometrine maleateIR84JPZ1RK57432-61-8NOFOWWRHEPHDCY-DAUURJMHSA-N
Methylergonovine tartrate5EDH242U9O6209-37-6KUTMUWFMKWZQBW-UQJJQXDBSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethergineTablet, coated.2 mg/1OralApotheca, Inc.2006-12-27Not applicableUs
MethergineTablet, coated.2 mg/1Oralbryant ranch prepack1946-11-19Not applicableUs
MethergineTablet, coated.2 mg/1OralPd Rx Pharmaceuticals, Inc.1946-11-192016-04-05Us
MethergineTablet, coated.2 mg/1OralDispensing Solutions, Inc.1946-11-19Not applicableUs
MethergineTablet, coated.2 mg/1OralPd Rx Pharmaceuticals, Inc.1946-11-192016-04-05Us00078 0054 05 nlmimage10 e208f107
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethergineTablet.2 mg/1OralLupin Pharma2016-04-04Not applicableUs
MethergineTablet.2 mg/1OralAvera Mc Kennan Hospital2016-06-23Not applicableUs
Methylergonovine MaleateTablet.2 mg/1OralPd Rx Pharmaceuticals, Inc.2011-08-01Not applicableUs
Methylergonovine MaleateTablet.2 mg/1OralKaiser Foundations Hospitals2012-05-31Not applicableUs
Methylergonovine MaleateTablet.2 mg/1OralGavis Pharmaceuticals, LLC.2011-06-15Not applicableUs
Methylergonovine MaleateTablet.2 mg/1OralPharmacist Pharmaceutical, LLC2011-08-01Not applicableUs
Methylergonovine MaleateInjection.2 mg/mLIntravenousBreckenridge Pharmaceutical, Inc.2016-11-07Not applicableUs
Methylergonovine MaleateInjection.2 mg/mLIntramuscular; IntravenousAkorn2011-03-02Not applicableUs
Methylergonovine MaleateTablet.2 mg/1OralRemedy Repack2013-02-252016-10-13Us
Methylergonovine MaleateTablet.2 mg/1OralAmerincan Health Packaging2012-05-012016-10-13Us43386 0140 28 nlmimage10 2d3c96b4
International/Other Brands
Basofortina (Novartis) / Bledstop (Caprifarmindo) / Demergin (Demo) / Ergogin (Cipla) / Ergomed (Medlink) / Ergomin (Alico Impex) / Ergotyl (Sandoz) / Expogin (L.B.S.) / Glomethyl (Metiska) / Ingagen-M (Inga) / Mem (Elin) / Mergot (Lloyd) / Mergotrex (Rotexmedica) / Metenarin / Metermin (Cadila) / Méthergin (Novartis) / Methergin (Novartis) / Methergine / Metherinal (Landson) / Metherspan (Opsonin) / Methovin (Kimia Farma) / Methylergobrevin (Hemofarm) / Methylergometrin (Spofa) / Metilat (Metiska) / Metiler (Adeka) / Metilergometrina (Hospira Italia) / Metrine (T P Drug) / Metrol (Simed) / Metvell (Novell) / Myomergin (Ethica Industri Farmasi) / Myometril (Oriental Chemical Works) / Neo-ergo (Oriental) / Partan M (Mochida) / Pospargin (Kalbe) / Satergin (Tablets) / Usamema (Icon) / Utergin (Svizera) / Uterine (LBS) / Uterjin (Münir Sahin) / Uterowin (Bestochem) / Utesel (Osel)
Categories
UNII
W53L6FE61V
CAS number
113-42-8
Weight
Average: 339.4314
Monoisotopic: 339.194677059
Chemical Formula
C20H25N3O2
InChI Key
UNBRKDKAWYKMIV-QWQRMKEZSA-N
InChI
InChI=1S/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1
IUPAC Name
(4R,7R)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][[email protected]@]12CC3=CNC4=CC=CC(=C34)C1=C[[email protected]](CN2C)C(=O)N[[email protected]@H](CC)CO

Pharmacology

Indication

For the prevention and control of excessive bleeding following vaginal childbirth

Structured Indications
Pharmacodynamics

Methylergometrine is a semisynthetic ergot alkaloid and a derivative of ergonovine and is used for the prevention and control of postpartum and post-abortion hemorrhage. In general, the effects of all the ergot alkaloids appear to results from their actions as partial agonists or antagonists at adrenergic, dopaminergic, and tryptaminergic receptors. The spectrum of effects depends on the agent, dosage, species, tissue, and experimental or physiological conditions. All of the alkaloids of ergot significantly increase the motor activity of the uterus. After small doses contractions are increased in force or frequency, or both, but are followed by a normal degree of relaxation. As the dose is increased, contractions become more forceful and prolonged, resting tonus is markedly increased, and sustained contracture can result.

Mechanism of action

Methylergometrine acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions through binding and the resultant antagonism of the dopamine D1 receptor. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss.

TargetActionsOrganism
AD(1A) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2BNot AvailableHuman
Absorption

Absorption is rapid after oral (60% bioavailability) and intramuscular (78% bioavailability) administration.

Volume of distribution
  • 56.1 ± 0 L
Protein binding
Not Available
Metabolism

Hepatic, with extensive first-pass metabolism.

Route of elimination

Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.

Half life

3.39 hours

Clearance
Not Available
Toxicity

Signs and symptoms of overexposure: hypertension, seizures, headache, hypotension, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Methylergometrine can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Methylergometrine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Methylergometrine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AcebutololAcebutolol may increase the vasoconstricting activities of Methylergometrine.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Acetazolamide.Approved, Vet Approved
AdrafinilMethylergometrine may increase the hypertensive activities of Adrafinil.Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Aldesleukin.Approved
AlmotriptanMethylergometrine may increase the vasoconstricting activities of Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Methylergometrine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Methylergometrine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the vasoconstricting activities of Methylergometrine.Approved, Withdrawn
AmbroxolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ambroxol.Approved
AmibegronMethylergometrine may increase the hypertensive activities of Amibegron.Investigational
AmitrazMethylergometrine may increase the hypertensive activities of Amitraz.Vet Approved
AmlodipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Amlodipine.Approved
AmprenavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Amprenavir.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Anastrozole.Approved, Investigational
AnisodamineMethylergometrine may increase the hypertensive activities of Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Antipyrine.Approved
Antithrombin III humanThe serum concentration of Methylergometrine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Methylergometrine can be increased when it is combined with Apixaban.Approved
ApomorphineMethylergometrine may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineMethylergometrine may increase the hypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Methylergometrine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineMethylergometrine may increase the hypertensive activities of Arbutamine.Approved
ArformoterolMethylergometrine may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Methylergometrine can be increased when it is combined with Argatroban.Approved, Investigational
ArotinololArotinolol may increase the vasoconstricting activities of Methylergometrine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Methylergometrine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the vasoconstricting activities of Methylergometrine.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Atorvastatin.Approved
AzelastineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Azelastine.Approved
AzithromycinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Azithromycin.Approved
BatimastatThe serum concentration of Methylergometrine can be increased when it is combined with Batimastat.Experimental
BefunololBefunolol may increase the vasoconstricting activities of Methylergometrine.Experimental
BenazeprilThe serum concentration of Methylergometrine can be increased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Methylergometrine can be increased when it is combined with Benzamidine.Experimental
BetamethasoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the vasoconstricting activities of Methylergometrine.Approved
BevantololBevantolol may increase the vasoconstricting activities of Methylergometrine.Approved
BicalutamideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Bicalutamide.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Bifonazole.Approved
BisoprololBisoprolol may increase the vasoconstricting activities of Methylergometrine.Approved
BitolterolMethylergometrine may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Methylergometrine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Methylergometrine can be increased when it is combined with Boceprevir.Withdrawn
BopindololBopindolol may increase the vasoconstricting activities of Methylergometrine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Bortezomib.Approved, Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Brentuximab vedotin.Approved
BrimonidineMethylergometrine may increase the hypertensive activities of Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the vasoconstricting activities of Methylergometrine.Investigational
BufuralolBufuralol may increase the vasoconstricting activities of Methylergometrine.Experimental, Investigational
BupranololBupranolol may increase the vasoconstricting activities of Methylergometrine.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cabergoline.Approved
CaffeineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Caffeine.Approved
CamostatThe serum concentration of Methylergometrine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Methylergometrine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Methylergometrine can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Capsaicin.Approved
CaptoprilThe serum concentration of Methylergometrine can be increased when it is combined with Captopril.Approved
CarbomycinThe serum concentration of Methylergometrine can be increased when it is combined with Carbomycin.Vet Approved
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Methylergometrine.Approved
CarteololCarteolol may increase the vasoconstricting activities of Methylergometrine.Approved
CarvedilolCarvedilol may increase the vasoconstricting activities of Methylergometrine.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Caspofungin.Approved
CeliprololCeliprolol may increase the vasoconstricting activities of Methylergometrine.Approved, Investigational
CeritinibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Methylergometrine.Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Methylergometrine can be increased when it is combined with Cholesterol.Experimental
ChymostatinThe serum concentration of Methylergometrine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Methylergometrine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Methylergometrine can be increased when it is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cilostazol.Approved
CiprofloxacinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ciprofloxacin.Approved, Investigational
CirazolineMethylergometrine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Methylergometrine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clemastine.Approved
ClenbuterolMethylergometrine may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClindamycinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clofazimine.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clomifene.Approved, Investigational
ClonidineMethylergometrine may increase the hypertensive activities of Clonidine.Approved
CloranololCloranolol may increase the vasoconstricting activities of Methylergometrine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clozapine.Approved
CobicistatThe serum concentration of Methylergometrine can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cocaine.Approved, Illicit
ColchicineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Colchicine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cortisone acetate.Approved
CrizotinibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Crizotinib.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Methylergometrine can be increased when it is combined with Dabigatran etexilate.Approved
DalfopristinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dalfopristin.Approved
DanazolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Danazol.Approved
DarexabanThe serum concentration of Methylergometrine can be increased when it is combined with Darexaban.Investigational
DarunavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Darunavir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Daunorubicin.Approved
DelanzomibThe serum concentration of Methylergometrine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Methylergometrine can be increased when it is combined with Delapril.Experimental
DelavirdineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Desipramine.Approved
DetomidineMethylergometrine may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineMethylergometrine may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Diazepam.Approved, Illicit, Vet Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Diethylstilbestrol.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methylergometrine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methylergometrine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Methylergometrine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methylergometrine.Approved
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dimethyl sulfoxide.Approved, Vet Approved
DipivefrinMethylergometrine may increase the hypertensive activities of Dipivefrin.Approved
DobutamineMethylergometrine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Docetaxel.Approved, Investigational
DopexamineMethylergometrine may increase the hypertensive activities of Dopexamine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Dronedarone.Approved
DroxidopaMethylergometrine may increase the hypertensive activities of Droxidopa.Approved, Investigational
EcabetThe serum concentration of Methylergometrine can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Econazole.Approved
EdoxabanThe serum concentration of Methylergometrine can be increased when it is combined with Edoxaban.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Methylergometrine can be increased when it is combined with Elafin.Investigational
ElbasvirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Elbasvir.Approved
EletriptanMethylergometrine may increase the vasoconstricting activities of Eletriptan.Approved, Investigational
EnalaprilThe serum concentration of Methylergometrine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Methylergometrine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Enasidenib.Approved
EpanololEpanolol may increase the vasoconstricting activities of Methylergometrine.Experimental
EphedrineMethylergometrine may increase the hypertensive activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Methylergometrine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Methylergometrine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the vasoconstricting activities of Methylergometrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ethanol.Approved
EtilefrineMethylergometrine may increase the hypertensive activities of Etilefrine.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Etoricoxib.Approved, Investigational
EzetimibeThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ezetimibe.Approved
FaldaprevirThe serum concentration of Methylergometrine can be increased when it is combined with Faldaprevir.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Felodipine.Approved, Investigational
FenoterolMethylergometrine may increase the hypertensive activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluoxetine.Approved, Vet Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Methylergometrine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluvoxamine.Approved, Investigational
FormoterolMethylergometrine may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fosamprenavir.Approved
FosaprepitantThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Methylergometrine can be increased when it is combined with Fosinopril.Approved
FrovatriptanMethylergometrine may increase the vasoconstricting activities of Frovatriptan.Approved, Investigational
GabexateThe serum concentration of Methylergometrine can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Methylergometrine can be increased when it is combined with Geldanamycin.Experimental
GemfibrozilThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Gemfibrozil.Approved
GlyburideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Glycerol Phenylbutyrate.Approved
GM6001The serum concentration of Methylergometrine can be increased when it is combined with GM6001.Experimental
GuanabenzMethylergometrine may increase the hypertensive activities of Guanabenz.Approved
GuanfacineMethylergometrine may increase the hypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Haloperidol.Approved
HexoprenalineMethylergometrine may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineMethylergometrine may increase the hypertensive activities of Higenamine.Investigational
HistamineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Histamine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Methylergometrine can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ifosfamide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Iloperidone.Approved
ImatinibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Imatinib.Approved
ImidaprilThe serum concentration of Methylergometrine can be increased when it is combined with Imidapril.Investigational
IndenololIndenolol may increase the vasoconstricting activities of Methylergometrine.Withdrawn
IndinavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Indinavir.Approved
indisulamThe risk or severity of adverse effects can be increased when Methylergometrine is combined with indisulam.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Irinotecan.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Isavuconazonium.Approved, Investigational
IsoetarineMethylergometrine may increase the hypertensive activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Methylergometrine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Isoniazid.Approved
IsoprenalineMethylergometrine may increase the hypertensive activities of Isoprenaline.Approved
IsoxsuprineMethylergometrine may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Methylergometrine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Methylergometrine can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Methylergometrine can be increased when it is combined with Josamycin.Approved
KetazolamThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Methylergometrine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Methylergometrine can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the vasoconstricting activities of Methylergometrine.Approved
LandiololLandiolol may increase the vasoconstricting activities of Methylergometrine.Investigational
LansoprazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lapatinib.Approved, Investigational
LepirudinThe serum concentration of Methylergometrine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Methylergometrine can be increased when it is combined with Letaxaban.Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Methylergometrine.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Levosalbutamol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Methylergometrine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Methylergometrine.Approved
LofexidineMethylergometrine may increase the hypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lomustine.Approved
LopinavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Loratadine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Methylergometrine.Approved
LosartanThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Methylergometrine.Approved, Investigational
LuliconazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Luliconazole.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Methylergometrine.Illicit, Withdrawn
ManidipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Manidipine.Approved
MedetomidineMethylergometrine may increase the hypertensive activities of Medetomidine.Vet Approved
MefloquineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mefloquine.Approved
MelagatranThe serum concentration of Methylergometrine can be increased when it is combined with Melagatran.Experimental
MephentermineMethylergometrine may increase the hypertensive activities of Mephentermine.Approved
MepindololMepindolol may increase the vasoconstricting activities of Methylergometrine.Experimental
MequitazineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mequitazine.Approved
MetaraminolMethylergometrine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Methylergometrine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Methimazole.Approved
MethoxamineMethylergometrine may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineMethylergometrine may increase the hypertensive activities of Methoxyphenamine.Experimental
MethyldopaMethylergometrine may increase the hypertensive activities of Methyldopa.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Methylprednisolone.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Methylergometrine.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Methylergometrine.Approved
MetoprololMetoprolol may increase the vasoconstricting activities of Methylergometrine.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Metronidazole.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Metyrapone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Methylergometrine.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mibefradil.Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Midazolam.Approved, Illicit
MidodrineMethylergometrine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mifepristone.Approved, Investigational
MirabegronMethylergometrine may increase the hypertensive activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mirtazapine.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Mitoxantrone.Approved, Investigational
ModafinilThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Methylergometrine can be increased when it is combined with Moexipril.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Methylergometrine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may increase the vasoconstricting activities of Methylergometrine.Approved
NafamostatThe serum concentration of Methylergometrine can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineMethylergometrine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanMethylergometrine may increase the vasoconstricting activities of Naratriptan.Approved, Investigational
NebivololMethylergometrine may increase the hypertensive activities of Nebivolol.Approved, Investigational
NelfinavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nelfinavir.Approved
NetupitantThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Netupitant.Approved
NevirapineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Methylergometrine.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nicotinamide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nifedipine.Approved
NilotinibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nilvadipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Methylergometrine can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinMethylergometrine may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NorepinephrineMethylergometrine may increase the hypertensive activities of Norepinephrine.Approved
NorfenefrineMethylergometrine may increase the hypertensive activities of Norfenefrine.Experimental
NorfloxacinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Norfloxacin.Approved
NoscapineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Noscapine.Investigational
NylidrinMethylergometrine may increase the hypertensive activities of Nylidrin.Approved
OctopamineMethylergometrine may increase the hypertensive activities of Octopamine.Experimental
OlanzapineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Olanzapine.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Olaparib.Approved
OleandomycinThe serum concentration of Methylergometrine can be increased when it is combined with Oleandomycin.Vet Approved
OlodaterolMethylergometrine may increase the hypertensive activities of Olodaterol.Approved
OmapatrilatThe serum concentration of Methylergometrine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineMethylergometrine may increase the hypertensive activities of Orciprenaline.Approved
OtamixabanThe serum concentration of Methylergometrine can be increased when it is combined with Otamixaban.Investigational
OxprenololOxprenolol may increase the vasoconstricting activities of Methylergometrine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Oxybutynin.Approved, Investigational
OxyfedrineMethylergometrine may increase the hypertensive activities of Oxyfedrine.Experimental
OxymetazolineMethylergometrine may increase the hypertensive activities of Oxymetazoline.Approved
OxymetholoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Palbociclib.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Paramethasone.Approved
PazopanibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Pazopanib.Approved
PenbutololPenbutolol may increase the vasoconstricting activities of Methylergometrine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Methylergometrine can be increased when it is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Phenelzine.Approved
PhenylephrineMethylergometrine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineMethylergometrine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhosphoramidonThe serum concentration of Methylergometrine can be increased when it is combined with Phosphoramidon.Experimental
PiclozotanMethylergometrine may increase the vasoconstricting activities of Piclozotan.Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Pilocarpine.Approved
PimozideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Pimozide.Approved
PindololPindolol may increase the vasoconstricting activities of Methylergometrine.Approved
PirbuterolMethylergometrine may increase the hypertensive activities of Pirbuterol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Methylergometrine.Approved
PosaconazoleThe serum concentration of Methylergometrine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the vasoconstricting activities of Methylergometrine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Methylergometrine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Prednisone.Approved, Vet Approved
PrenalterolMethylergometrine may increase the hypertensive activities of Prenalterol.Experimental
PrimaquineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Primaquine.Approved
PrinomastatThe serum concentration of Methylergometrine can be increased when it is combined with Prinomastat.Investigational
ProcaterolMethylergometrine may increase the hypertensive activities of Procaterol.Approved
ProgesteroneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Progesterone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the vasoconstricting activities of Methylergometrine.Approved, Investigational
PRX-00023Methylergometrine may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineMethylergometrine may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilThe serum concentration of Methylergometrine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinidine.Approved
QuinineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinupristin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Methylergometrine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineMethylergometrine may increase the hypertensive activities of Racepinephrine.Approved
RactopamineMethylergometrine may increase the hypertensive activities of Ractopamine.Vet Approved
RaloxifeneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Raloxifene.Approved, Investigational
RamiprilThe serum concentration of Methylergometrine can be increased when it is combined with Ramipril.Approved
RanitidineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ranitidine.Approved
RanolazineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ranolazine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Regorafenib.Approved
RemikirenThe serum concentration of Methylergometrine can be increased when it is combined with Remikiren.Approved
RepaglinideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Repaglinide.Approved, Investigational
ReproterolMethylergometrine may increase the hypertensive activities of Reproterol.Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Resveratrol.Experimental, Investigational
RilmenidineMethylergometrine may increase the hypertensive activities of Rilmenidine.Investigational
RilpivirineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Rilpivirine.Approved
RimiterolMethylergometrine may increase the hypertensive activities of Rimiterol.Experimental
RisperidoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Risperidone.Approved, Investigational
RitobegronMethylergometrine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineMethylergometrine may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Methylergometrine can be increased when it is combined with Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Rivastigmine.Approved, Investigational
RizatriptanMethylergometrine may increase the vasoconstricting activities of Rizatriptan.Approved
RolitetracyclineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Rolitetracycline.Approved
RomifidineMethylergometrine may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleMethylergometrine may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Methylergometrine.Approved
RoxithromycinThe serum concentration of Methylergometrine can be increased when it is combined with Roxithromycin.Approved, Withdrawn
RutinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Rutin.Experimental
S-3304The serum concentration of Methylergometrine can be increased when it is combined with S-3304.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Salbutamol.Approved, Vet Approved
SalmeterolMethylergometrine may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Saquinavir.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sarilumab.Approved
SaxagliptinThe serum concentration of Methylergometrine can be increased when it is combined with Saxagliptin.Approved
SertralineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sertraline.Approved
SildenafilThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sildenafil.Approved, Investigational
SimeprevirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Methylergometrine.Approved
SirolimusThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Methylergometrine can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Methylergometrine can be increased when it is combined with Sivelestat.Investigational
SolabegronMethylergometrine may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Methylergometrine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the vasoconstricting activities of Methylergometrine.Approved
SpiraprilThe serum concentration of Methylergometrine can be increased when it is combined with Spirapril.Approved
StiripentolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Stiripentol.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfamethoxazole.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfanilamide.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanMethylergometrine may increase the vasoconstricting activities of Sumatriptan.Approved, Investigational
SynephrineMethylergometrine may increase the hypertensive activities of Synephrine.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tacrolimus.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tadalafil.Approved, Investigational
TalinololTalinolol may increase the vasoconstricting activities of Methylergometrine.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tamoxifen.Approved
TelaprevirThe serum concentration of Methylergometrine can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Methylergometrine can be increased when it is combined with Telithromycin.Approved
TemocaprilThe serum concentration of Methylergometrine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Teniposide.Approved
TerbutalineMethylergometrine may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Methylergometrine.Experimental
TertatololTertatolol may increase the vasoconstricting activities of Methylergometrine.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Testosterone.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tetracycline.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Methylergometrine can be increased when it is combined with Thiorphan.Experimental
TicagrelorThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ticlopidine.Approved
TimololTimolol may increase the vasoconstricting activities of Methylergometrine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tioconazole.Approved
TipranavirThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tipranavir.Approved, Investigational
TizanidineMethylergometrine may increase the hypertensive activities of Tizanidine.Approved
TofisopamThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tofisopam.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Topiroxostat.Approved
TopotecanThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Topotecan.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Methylergometrine can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Tranylcypromine.Approved
TretoquinolMethylergometrine may increase the hypertensive activities of Tretoquinol.Experimental
TroglitazoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Troglitazone.Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Troleandomycin.Approved
TulobuterolMethylergometrine may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Methylergometrine can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Methylergometrine can be increased when it is combined with Ubenimex.Experimental
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Methylergometrine.Experimental
UlinastatinThe serum concentration of Methylergometrine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Venlafaxine.Approved
VilazodoneMethylergometrine may increase the vasoconstricting activities of Vilazodone.Approved
VildagliptinThe serum concentration of Methylergometrine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Vincristine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Methylergometrine can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineMethylergometrine may increase the vasoconstricting activities of Vortioxetine.Approved
XamoterolMethylergometrine may increase the hypertensive activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Methylergometrine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineMethylergometrine may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Methylergometrine may increase the hypertensive activities of YM-178.Investigational
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Methylergometrine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Methylergometrine can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanMethylergometrine may increase the vasoconstricting activities of Zolmitriptan.Approved, Investigational
ZucapsaicinThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Zucapsaicin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14497
KEGG Drug
D00680
PubChem Compound
8226
PubChem Substance
46507746
ChemSpider
7933
BindingDB
50330860
ChEBI
92607
ChEMBL
CHEMBL1201356
Therapeutic Targets Database
DAP000978
PharmGKB
PA450461
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Methylergonovine
ATC Codes
G02AC01 — Methylergometrine and oxytocinG02AB01 — Methylergometrine
MSDS
Download (42.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentPostpartum Hemorrhage / Uterine Atony / Uterine tone disorders1
4CompletedTreatmentArterial Hypotension / Uterine Atony1
4RecruitingPreventionHemorrhage1
Not AvailableCompletedPreventionEndometritis1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Pharmaforce inc
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedOral.2 mg/1
InjectionIntramuscular; Intravenous.2 mg/mL
InjectionIntravenous.2 mg/mL
Injection, solutionIntramuscular; Intravenous.2 mg/mL
TabletOral.2 mg/1
Prices
Unit descriptionCostUnit
Methergine 0.2 mg/ml ampul7.81USD ml
Methylergonovine 0.2 mg/ml vial5.28USD ml
Methergine 0.2 mg tablet1.42USD tablet
Norforms fem deodorant suppository0.29USD suppository
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)172 °CPhysProp
water solubility25 mg/mLNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.204 mg/mLALOGPS
logP1.74ALOGPS
logP1.59ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)15ChemAxon
pKa (Strongest Basic)7.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area68.36 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity99.58 m3·mol-1ChemAxon
Polarizability38.73 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.6556
Caco-2 permeable-0.8726
P-glycoprotein substrateSubstrate0.8604
P-glycoprotein inhibitor INon-inhibitor0.874
P-glycoprotein inhibitor IINon-inhibitor0.8959
Renal organic cation transporterNon-inhibitor0.7798
CYP450 2C9 substrateNon-substrate0.8316
CYP450 2D6 substrateNon-substrate0.8979
CYP450 3A4 substrateSubstrate0.664
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8641
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8959
Ames testNon AMES toxic0.5734
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable0.8422
Rat acute toxicity3.5304 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9614
hERG inhibition (predictor II)Inhibitor0.5889
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergamides
Alternative Parents
Indoloquinolines / Benzoquinolines / Quinoline-3-carboxamides / Pyrroloquinolines / 3-alkylindoles / Isoindoles and derivatives / Aralkylamines / Benzenoids / Heteroaromatic compounds / Pyrroles
show 9 more
Substituents
Lysergic acid amide / Indoloquinoline / Benzoquinoline / Pyrroloquinoline / Quinoline-3-carboxamide / Quinoline / 3-alkylindole / Indole / Indole or derivatives / Isoindole or derivatives
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Reyes FD, Mozzachiodi R, Baxter DA, Byrne JH: Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20. [PubMed:15930499]
  4. Nargeot R, Baxter DA, Patterson GW, Byrne JH: Dopaminergic synapses mediate neuronal changes in an analogue of operant conditioning. J Neurophysiol. 1999 Apr;81(4):1983-7. [PubMed:10200235]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. [PubMed:11104741]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Moubarak AS, Rosenkrans CF Jr, Johnson ZB: Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9. [PubMed:12583687]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:35